Genomics & Omics Analysis - software & AI news

Daily news on software, AI, and companies shaping genomics & omics analysis.

Showing 47 results
A minimalist illustration of an ECG waveform and DNA helix on a solid background.

Jun 13, 2026

New FDA Clearances for Genomics and Cardiac AI Could Be A Game Changer For Tempus AI (TEM)

Tempus AI has recently achieved significant FDA approvals that could enhance its position in the precision medicine landscape. The company received clearance for its xT CDx sequencing platform focused on tumor-only indications and published a validation study for its ECG-AF software, which predicts the risk of atrial fibrillation or flutter over the next year.These developments highlight Tempus AI's strategy to integrate extensive genomic data with AI technologies, aiming to improve decision-mak
A minimalist representation of a genome and a cell in a dark palette.

Jun 11, 2026

Infosys-backed 4baseCare Raises INR 128 Cr to Advance Oncology Platform Globally

4baseCare, a precision oncology startup backed by Infosys, has successfully raised INR 128 crore in Series B funding to enhance its global oncology platform, OncoTwin. This investment aims to expand its genomics laboratory network and improve access to precision oncology, particularly for underrepresented populations in various regions.The funding round included a significant top-up of INR 38 crore led by growX Ventures and Infosys, with contributions from existing investors. This capital will e
A minimalist illustration of a DNA strand and data points representing precision oncology.

Jun 10, 2026

Sophia Genetics, Memorial Sloan Kettering Sign Strategic Collaboration for AI-Powered Precision Oncology Hub

Memorial Sloan Kettering Cancer Center and Sophia Genetics have announced a strategic collaboration to create an AI-powered precision oncology hub aimed at enhancing cancer care through advanced analytics and clinical expertise.The partnership will leverage Memorial Sloan Kettering's extensive clinical datasets and expertise along with Sophia Genetics' AI-driven analytics platform. This initiative seeks to establish a global hub for precision medicine, integrating the strengths of both organizat
A blood sample in a test tube on a lab bench

Jun 9, 2026

Machine Learning Model Enhances Precision of Liquid Biopsy Diagnostics

Researchers at Johns Hopkins Kimmel Cancer Center have developed a groundbreaking machine learning model named plasmaCHORD, aimed at enhancing the accuracy of mutation identification in liquid biopsies for cancer diagnostics. This innovative tool significantly improves the clinical decision-making process by effectively distinguishing between cancer-derived mutations and those from other biological processes, which is crucial for targeted therapeutic interventions.Liquid biopsies have revolution
A minimalist representation of a mass spectrometer and a molecule in a dark color scheme.

Jun 8, 2026

Did New Orbitrap and AI Proteomics Launches Just Reframe Thermo Fisher Scientific's (TMO) Tools Integration Story?

Thermo Fisher Scientific has introduced its new Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers, showcasing advancements in multiomics and AI-enabled proteomics at the recent American Society for Mass Spectrometry Conference. These innovations aim to enhance the detection of low-abundance molecules, thereby supporting complex biopharmaceutical research and regulatory compliance.The launches are significant as they reinforce Thermo Fisher's strategy to bridge early biological disco
A blood sample in a vial on a lab bench with a microscope behind it.

Jun 8, 2026

Our vision is to make genomics as commonplace as BP monitor: Dr. Ramesh Hariharan, Chief Executive Officer, Strand Life Sciences

Strand Life Sciences is positioning itself to integrate genomics into everyday healthcare, aiming to make genomic insights as commonplace as traditional monitoring tools like blood pressure monitors. In a recent interview, CEO Dr. Ramesh Hariharan discussed the company's strategic evolution in precision medicine, diagnostics, and consumer genomics.As precision medicine gains traction in India, Strand Life Sciences is expanding its focus from enterprise bioinformatics to include diagnostics and p
A tissue sample on a laboratory countertop with a notebook in the background.

Jun 6, 2026

Is Tempus AI’s (TEM) New Oncology Tools Quietly Redefining Its Precision Medicine Moat?

Tempus AI is making significant strides in oncology with recent advancements that include FDA approval for its xT CDx tumor-only sequencing platform and the upcoming launch of its xH whole-genome test. These innovations are part of a broader strategy to integrate AI into precision medicine, aiming to create a comprehensive infrastructure for diagnostics and drug development.With the FDA's endorsement of the xT CDx platform, Tempus AI is poised to enhance its market position by potentially conver
A tumor sample on a microscope slide in a dimly lit lab

Jun 4, 2026

SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center

SOPHiA GENETICS has announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK) to establish a precision medicine hub aimed at advancing precision oncology.The Memorandum of Understanding (MOU) between SOPHiA GENETICS and MSK seeks to leverage the strengths of both organizations. SOPHiA’s DDM™ platform has analyzed over 2.5 million cases since its inception, while MSK has sequenced more than 150,000 tumor samples, creating a rich dataset that integrates clinical outcome
A stack of research papers in a dimly lit lab, symbolizing human genetics data.

Jun 4, 2026

Genomics Launches Mystra AI Platform to Accelerate Drug Target Discovery Using Human Genetics Data

Genomics has introduced the Mystra AI platform, aiming to enhance drug target discovery by leveraging extensive human genetics data.The London-based techbio company has developed Mystra AI, a conversational AI tool designed to facilitate drug target identification and validation. This platform is already in use by prominent pharmaceutical companies and biotech startups, addressing the high failure rates in drug development, where approximately 95% of candidates fail in clinical trials. Genomics
A DNA sequencing sample on a lab bench with a pipette

Jun 3, 2026

AI tool simplifies and scales complete genome assembly, supporting advances in diagnostics and precision medicine

An innovative AI tool called HERRO has been developed to enhance the accuracy and efficiency of complete genome assemblies, potentially revolutionizing diagnostics and precision medicine.HERRO, created by an international team led by the A*STAR Genome Institute of Singapore, utilizes deep learning to rectify errors in nanopore sequencing reads from Oxford Nanopore Technologies (ONT). This technology is particularly valuable for reading long DNA sequences, which are essential for analyzing comple
Minimalist illustration of DNA and graph line representing genomics data

Jun 3, 2026

M42, Arcera team up to boost medicine and biotech growth in Abu Dhabi

A new collaboration between M42 and Arcera aims to enhance the life sciences landscape in Abu Dhabi, focusing on a comprehensive ecosystem for clinical development and innovative therapies.The partnership is set to leverage the strengths of both organizations, with M42 bringing its expertise in healthcare and artificial intelligence, while Arcera contributes its experience in drug development and market access. Together, they will utilize genomics data to investigate the prevalence of selected g
A minimalist representation of a blood droplet and an immune cell silhouette.

Jun 2, 2026

London biotech raises $53M to decode the immune system using a single blood sample

IMU Biosciences has successfully raised over $53 million in an extended Series A funding round, aimed at revolutionizing immune system analysis through advanced technology.The London-based biotech firm, co-led by IQ Capital and Molten Ventures, has developed the largest immune dataset in the world, encompassing over 25,000 individuals and generating more than 100 million immune data points from a single blood sample. This innovative approach addresses a significant gap in precision medicine, whe